Bosh sahifaEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
0,69 $
Seans yopilganidan keyin:(4,99%)+0,035
0,73 $
Yopilgan:22-noy, 17:20:18 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
0,72 $
Kunlik diapazon
0,67 $ - 0,74 $
Yillik diapazon
0,67 $ - 3,13 $
Bozor kapitalizatsiyasi
15,20 mln USD
Oʻrtacha hajm
90,14 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 4,13 mln | -10,38% |
Joriy xarajat | 4,85 mln | -10,01% |
Sof foyda | -2,07 mln | 38,42% |
Sof foyda marjasi | -50,18 | 31,30% |
Har bir ulushga tushum | — | — |
EBITDA | -2,23 mln | 10,97% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 8,29 mln | -16,55% |
Jami aktivlari | 29,21 mln | -6,33% |
Jami passivlari | 14,34 mln | -9,96% |
Umumiy kapital | 14,87 mln | — |
Tarqatilgan aksiyalar | 22,00 mln | — |
Narxi/balansdagi bahosi | 1,06 | — |
Aktivlardan daromad | -23,48% | — |
Kapitaldan daromad | -33,02% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -2,07 mln | 38,42% |
Operatsiyalardan naqd pul | -2,28 mln | 32,09% |
Sarmoyadan naqd pul | -8,00 ming | 52,94% |
Moliyadan naqd pul | 4,69 mln | — |
Naqd pulning sof oʻzgarishi | 2,41 mln | 171,42% |
Boʻsh pul | -1,11 mln | 57,80% |
Haqida
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
CEO
Tashkil etilgan
2005
Sayt
Xodimlar soni
70